Page last updated: 2024-11-05

ethyl 4-dimethylaminobenzoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ethyl 4-dimethylaminobenzoate: slow-acting amine polymerization accelerator [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

parbenate : A benzoate ester that is ethyl benzoate substituted by a dimethylamino group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID25127
CHEMBL ID3185245
CHEBI ID52073
SCHEMBL ID15425
MeSH IDM0097044

Synonyms (62)

Synonym
benzoic acid, 4-(dimethylamino)-, ethyl ester
ethyl 4-dimethylaminobenzoate
IDI1_014576
ethyl p-dimethylaminobenzoate
inchi=1/c11h15no2/c1-4-14-11(13)9-5-7-10(8-6-9)12(2)3/h5-8h,4h2,1-3h
ethyl 4-(dimethylamino)benzoate, >=99%
MAYBRIDGE3_003189
CHEBI:52073 ,
ethyl 4-(dimethylamino)benzoate
ethyl-p-dimethylaminobenzoate
parbenate
10287-53-3
HMS1440A21
4-(n,n-dimethylamino)benzoic acid ethyl ester
4-(dimethylamino)benzoic acid ethyl ester
D1744
A800637
NCGC00248207-01
ethyl-4-dimethylaminobenzoate
unii-829s8d3y0x
sb-pi 704
genocure epd
kayacure epa
n,n-dimethylbenzocaine
darocur ebd
829s8d3y0x ,
einecs 233-634-3
tox21_300913
dtxsid2044763 ,
dtxcid0024763
cas-10287-53-3
NCGC00254817-01
STL164077
AKOS005202997
FT-0616758
AE-562/43459976
edab
ethyl dimethyl paba
pl-edb
ethyl dimethyl paba [inci]
AM84309
SCHEMBL15425
4-(dimethylamino)-benzoic acid ethyl ester
4-dimethylamino-benzoic acid ethyl ester
speedcure edb
p-dimethylaminobenzoic acid ethyl ester
ethyl-4-(n,n-dimethylamino)benzoate
quantacure epd
benzoic acid, p-(dimethylamino)-, ethyl ester
W-108864
CHEMBL3185245
ethyl-4-dimethylamino benzoate
mfcd00009115
AC-8129
ethyl 4-(dimethylamino)benzoate, standard for quantitative nmr, tracecert(r)
ethyl 4-dimethylaminobenzoate, 99%
97003-31-1
CS-0030547
Q27123150
AS-14745
D72571
4-dimethylaminobenzoic acid-ethyl ester

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Catalase mildly reduced the toxic effect and carboxylesterase showed obvious ability to reverse the toxicity of DMABEE."( Cytotoxicity and genotoxicity of DMABEE, a co-photoinitiator of resin polymerization, on CHO-K1 cells: Role of redox and carboxylesterase.
Chang, HH; Chang, MC; Chen, YJ; Jeng, JH; Shih, WC; Tsai, YL; Wang, YL, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency35.57420.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.92220.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency48.55770.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency17.46610.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency17.22890.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.18010.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency7.97430.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency20.76570.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency54.48270.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.22980.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743079; AID743080; AID743091
aryl hydrocarbon receptorHomo sapiens (human)Potency61.53610.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency24.33650.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency48.55770.001628.015177.1139AID1259385
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.194919.739145.978464.9432AID1159509
histone deacetylase 9 isoform 3Homo sapiens (human)Potency11.68700.037617.082361.1927AID1259364; AID1259388
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency24.33650.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency24.33650.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.67)18.7374
1990's2 (6.67)18.2507
2000's6 (20.00)29.6817
2010's19 (63.33)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.63 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index5.13 (4.65)
Search Engine Demand Index39.48 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]